Tyra announced a Pricing of Upsized Initial Public Offerings, which is based on the actual price of the initial public offering
Compared to the original public offering, a 10-800,000 shares of common stock are announced today at an initial public price of $16. Tyra offers all the shares. The gross proceeds of the offer, before deducting underwriting discounts and commissions and other offering expenses payable by Tyra, will be about $172,8 million. The shares will begin trading on the global select market on September 15, 2021 under the ticker symbol "TYRA". As the initial public offering price increases, the underwriting offers will close on September 17 2021, subject to the usual conditions for closing. In addition, Tyra granted the Underwriters a 30-day option to buy up to one thousand
BofA Securities, Jefferies and Cowen are joint book-running managers for the offering.
The Securities and Exchange Commission filed an registration statement relating to the offering and became effective on September 14, 2021. The offering is only made through a prospectus. Upon order, copies of the final prospectus may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospect
This press release will not constitute an offer to sell or a solicitation of an offering to buy these securities, nor will this offer or sale of these goods in any state or jurisdiction in which such offer, solicit or sell would be unlawful prior
About Tyra, about the Tyrohnea story
Tyra Biosciences, Inc. is a precision oncology company that is focused on developing targeted therapies to treat cancer and improve outcomes for patients with cancer. The platform, which is optimized to allow rapid and precise refinement of structural design through iterative molecular SNPshots, is a new generation of product candidates that are specifically designed to address acquired drug resistance and provide Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7 % of all cancers. TYRA-300, the lead product candidate for Tyra's tyre, is designed to selectively inhibit FGFR3 by focusing on patients with bladder cancer.
Amy Conrad is [email protected] [soldier].
SOURCE Tyra Biosciences Inc.